Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT06712017Enrolling By Invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-Resectable
PrincipalinvestigatorStart date: 2024-08-22

Research Network

Collaboration Network

3 collaborators·3 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Beijing Tsinghua Changgeng Hospital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Wanguang Zhang, M.D.

Tongji Hospital

Moderately Similar
3 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-resectable
Similarity Score30%

Liangrong Shi, M.D.

Xiangya Hospital of Central South University

Moderately Similar
4 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-resectable
Similarity Score30%

Salah-Eddin Al-Batran, Prof. Dr.

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Moderately Similar
13 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-resectable
Similarity Score30%

Yefa Yang, MD

Eastern Hepatobiliary Surgery Hospital

Related
1 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-resectable

Worked with same sponsors:

GrandPharma (China) Co., Ltd.
Collaborated on 1 trial
Similarity Score24%

Kangshun Zhu, MD

Second Affiliated Hospital of Guangzhou Medical University

Related
4 trials

Shared therapeutic areas:

Hepatocellular Carcinoma Non-resectableHepatocellular Carcinoma (HCC)

Worked with same sponsors:

GrandPharma (China) Co., Ltd.
Collaborated on 1 trial
Similarity Score24%

Yan Sun, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
4 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)
Similarity Score15%

Tsang-Wu Liu

Taiwan Cooperative Oncology Group, NHRI

Related
5 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)
Similarity Score15%

Kangshun Zhu, Dr.

Second Affiliated Hospital of Guangzhou Medical University

Related
7 trials

Shared therapeutic areas:

Hepatocellular Carcinoma Non-resectable
Similarity Score15%

Sirish Kishore, MD

VA Palo Alto Health Care System

Related
3 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)
Similarity Score15%

Shuhang Wang

NCC, CICAMS

Related
5 trials

Shared therapeutic areas:

Hepatocellular Carcinoma (HCC)
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06712017PrincipalInvestigator

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma Non-Resectable
Enrolling By Invitation

All 1 trials loaded